Net sales of 808,544 million yen (Year-over-Year (YoY) 5.3% increase), operating income of 4,748 million yen (-34.6%), etc. Interim net income was 4,177 million yen (-33.1%), and the full-year forecast remains unchanged. Pharmaceutical wholesale segment was resilient but profit was pressured by higher costs. The company emphasizes progress in new alliances and business expansion and strengthening of the management foundation.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"8129","jir_company_name":"Toho Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-11","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/8129-20261111-01.pdf","jir_short_summary":"Net sales of 808,544 million yen (Year-over-Year (YoY) 5.3% increase), operating income of 4,748 million yen (-34.6%), etc. Interim net income was 4,177 million yen (-33.1%), and the full-year forecast remains unchanged. Pharmaceutical wholesale segment was resilient but profit was pressured by higher costs. The company emphasizes progress in new alliances and business expansion and strengthening of the management foundation.","jir_summary":"### Overview of Results\nFor the interim period, net sales amounted to 808,544 million yen, a 5.3% increase from the same period of the previous fiscal year, while operating income decreased significantly to 4,748 million yen (down 34.6%). Pharmaceutical wholesale remained steady, but higher raw material costs and increased expenses weighed on profits. By segment, pharmaceutical wholesale accounted for the largest share of sales, with dispensing pharmacies, pharmaceutical manufacturing and sales, and other peripheral businesses also contributing. Interim net income was 4,177 million yen, down 33.1% year-over-year. The full-year forecast remains unchanged. The company will continue to promote new alliances and strengthen its management foundation through DX and other initiatives.\n\n### Strategy and Future Outlook\nAs part of the mid-term management plan \"Soaring into the Next Era,\" the company is promoting growth strategies, efficiency improvements, and reinforcement of the management foundation. The company is expanding alliances and new business creation (including Allostem Sheet, Stemchymal, AdipoSeeds, etc.). It will pursue logistics and delivery efficiency, reduce indirect material costs, and streamline operations through DX, aiming to transform into a healthcare total solution provider. Measures to respond to external environmental changes such as drug price revisions will continue.","jir_financial_highlights":"Net Sales: 808,544 (YoY 5.3% increase)\nOperating Income: 4,748 (YoY -34.6% decrease)\nOrdinary Income: 6,553 (YoY -21.3% decrease)\nNet Income Attributable to Owners of Parent (Interim): 4,177 (YoY -33.1% decrease)\nInterim Net Income per Share: 64.10 (YoY -35.66% decrease)","jir_category":"","jir_hashtags":"#TohoHoldings, #FinancialSummary, #BySegment, #Interim, #MidTermManagementPlan","jir_key_figures":"Net Sales: 808,544 million yen (YoY 5.3% increase)\nOperating Income: 4,748 million yen (YoY -34.6%)\nNet Income Attributable to Owners of Parent (Interim): 4,177 million yen (YoY -33.1%)","jir_meta_title":"Toho Holdings Co., Ltd. - Financial Summary for Q2 FY2027 | Net Sales 808,544 million yen & Profit Trends","jir_meta_description":"Financial Summary for Toho Holdings Co., Ltd. for Q2 FY2027. Net sales 808,544 million yen, operating income 4,748 million yen, net income 4,177 million yen. Includes segment performance, strategy and progress on mid-term plan.","jir_og_title":"Reading Toho Holdings Co., Ltd.'s Financial Summary","jir_og_description":"Toho Holdings Co., Ltd. Q2 FY2027 financial summary: sales and profit trends and medium- to long-term growth strategy summarized.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[]","ir_related_company":8078,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-148277","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n